GTIAS Industry Analysis Available
This NAICS code maps to a fully analysed industry with an 81-attribute GTIAS scorecard, risk scenarios, and 42+ strategic frameworks.
View Industry Analysis →About This Industry
This U.S. industry comprises establishments primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.
Cross-References. Establishments primarily engaged in--
Manufacturing uncompounded medicinal chemicals and their derivatives--are classified in U.S. Industry 325411, Medicinal and Botanical Manufacturing;
Manufacturing in-vitro diagnostic substances--are classified in U.S. Industry 325413, In-Vitro Diagnostic Substance Manufacturing; and
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except for diagnostic use)--are classified in U.S. Industry 325414, Biological Product (except Diagnostic) Manufacturing.